
News|Articles|September 28, 2026
FAQ: How should clinicians manage histoplasmosis during pregnancy?
Author(s)Contemporary OB/GYN Staff
Fact checked by: Joshua Fitch, Senior Editor
Missed the updated IDSA histoplasmosis guideline? This easy-to-read FAQ covers what clinicians caring for pregnant patients need to know.
Advertisement
Advertisement
The Infectious Diseases Society of America (IDSA) has released the second part of its update to the clinical practice guideline on histoplasmosis in adults, children, and pregnant individuals. The newest section, posted September 16, 2026, is a consensus statement on initial antifungal treatment of severe pulmonary and disseminated histoplasmosis. It joins 2 recommendations from March 2025 on asymptomatic Histoplasma pulmonary nodules (histoplasmomas) and mild or moderate acute pulmonary histoplasmosis, and together these sections form the first 2 parts of an update to the 2007 IDSA guideline.
Related to this article

Patients with 3 or more adverse pregnancy outcomes had lower odds of postpartum contraceptive use in a PRAMS analysis of 222,412 individuals.

Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.

Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.

The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.

Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.

ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.

Risk factors cast a wide net in preeclampsia prediction, but biomarkers could add precision, according to Dallas Reed, MD.
Advertisement
Advertisement

